These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Progress in the Management of Smoldering Multiple Myeloma. Schmidt TM; Callander NS Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517 [TBL] [Abstract][Full Text] [Related]
4. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295 [TBL] [Abstract][Full Text] [Related]
5. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Kunacheewa C; Manasanch EE Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. González-Calle V; Mateos MV Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma. Schmidt T; Callander N J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744 [TBL] [Abstract][Full Text] [Related]
8. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Schmidt T; Gahvari Z; Callander NS Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):653-664. PubMed ID: 38641486 [TBL] [Abstract][Full Text] [Related]
9. Smoldering multiple myeloma: Reviewing the rationale for intervention. Gertz M Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298 [TBL] [Abstract][Full Text] [Related]
11. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818 [TBL] [Abstract][Full Text] [Related]
12. Risk Stratification of Precursors to Multiple Myeloma in 2020. Chudasama R; Barth P R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162 [TBL] [Abstract][Full Text] [Related]
13. Smoldering Multiple Myeloma: To Treat or Not to Treat. Kapoor P; Rajkumar SV Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862 [TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma 40 years later: a story of unintended disease. Yavorkovsky LL Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658 [No Abstract] [Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. Maciocia N; Wechalekar A; Yong K Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161 [TBL] [Abstract][Full Text] [Related]
17. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Kunacheewa C; Manasanch EE Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841 [TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper. Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718 [TBL] [Abstract][Full Text] [Related]
19. The consultant's guide to smoldering multiple myeloma. Thorsteinsdottir S; Kristinsson SY Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144 [TBL] [Abstract][Full Text] [Related]
20. Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia. Sharma D; Ungar B; Adalsteinsson JA; Sigurdsson JK; Sharp K; Thorsteinsdóttir S; Rögnvaldsson S; Þórðardóttir ÁR; Viðarsson B; Önundarson PT; Agnarssond BA; Sigurðardóttird M; Þorsteinsdóttir I; Ólafsson Í; Eyþórsson E; Jónsson Á; Ólafsson A; Gíslason GK; Landgren O; Hulcrantz M; Durie BG; Harding S; Love TJ; Kristinsson SY Arch Dermatol Res; 2024 Sep; 316(9):627. PubMed ID: 39276205 [No Abstract] [Full Text] [Related] [Next] [New Search]